[{"orgOrder":0,"company":"IntelGenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Montelukast Sodium","moa":"Cysteinyl leukotriene receptor 1","graph1":"Neurology","graph2":"Phase II","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"IntelGenx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IntelGenx \/ Inapplicable"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Montelukast Sodium","moa":"Cysteinyl leukotriene receptor 1","graph1":"Neurology","graph2":"Phase II","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"IntelGenx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IntelGenx \/ Inapplicable"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Montelukast Sodium","moa":"Cysteinyl leukotriene receptor 1","graph1":"Neurology","graph2":"Phase II","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"IntelGenx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IntelGenx \/ Inapplicable"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Montelukast Sodium","moa":"Cysteinyl leukotriene receptor 1","graph1":"Neurology","graph2":"Phase II","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"IntelGenx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IntelGenx \/ Inapplicable"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Montelukast Sodium","moa":"Cysteinyl leukotriene receptor 1","graph1":"Neurology","graph2":"Phase II","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"IntelGenx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IntelGenx \/ Inapplicable"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Montelukast Sodium","moa":"Cysteinyl leukotriene receptor 1","graph1":"Neurology","graph2":"Phase II","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"IntelGenx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IntelGenx \/ Inapplicable"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Montelukast Sodium","moa":"Cysteinyl leukotriene receptor 1","graph1":"Neurology","graph2":"Phase II","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"IntelGenx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IntelGenx \/ Inapplicable"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Karolinska Institute","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Montelukast Sodium","moa":"Cysteinyl leukotriene receptor 1","graph1":"Neurology","graph2":"Phase II","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"IntelGenx \/ Karolinska Institute","highestDevelopmentStatusID":"8","companyTruncated":"IntelGenx \/ Karolinska Institute"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Montelukast Sodium","moa":"Cysteinyl leukotriene receptor 1","graph1":"Neurology","graph2":"Phase II","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"IntelGenx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IntelGenx \/ Inapplicable"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Karolinska University Hospital","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Montelukast Sodium","moa":"Cysteinyl leukotriene receptor 1","graph1":"Neurology","graph2":"Phase II","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"IntelGenx \/ Karolinska University Hospital","highestDevelopmentStatusID":"8","companyTruncated":"IntelGenx \/ Karolinska University Hospital"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Montelukast Sodium","moa":"Cysteinyl leukotriene receptor 1","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Qilu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"Qilu Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Qilu Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Montelukast Sodium","moa":"Cysteinyl leukotriene receptor 1","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Qilu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"Qilu Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Qilu Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Novateur Ventures","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Zileuton","moa":"||Arachidonate 5-lipoxygenase","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Novateur Ventures","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novateur Ventures \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Novateur Ventures \/ Inapplicable"}]
Find Clinical Drug Pipeline Developments & Deals for Montelukast Sodium
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
